Our study also investigated several gene mutations commonly used for screening, such as Mediterranean anemia-related genes HBA and HBB, progressive muscular dystrophy-related gene DMD, spinal muscular atrophy-related gene SMN1, and phenylketonuria-related gene PAH, confirming their high mutation rates and clinical value. This evidence concerns the gene SMN1 and beta-thalassemia major.